Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Short Interest Up 816.3% in February

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) was the recipient of a significant growth in short interest in the month of February. As of February 27th, there was short interest totaling 8,036 shares, a growth of 816.3% from the February 12th total of 877 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 92,565 shares, the days-to-cover ratio is currently 0.1 days. Based on an average daily volume of 92,565 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.0% of the shares of the company are sold short.

Barinthus Biotherapeutics Price Performance

Shares of Barinthus Biotherapeutics stock traded up $0.01 during midday trading on Thursday, hitting $0.60. The company had a trading volume of 6,492 shares, compared to its average volume of 48,654. Barinthus Biotherapeutics has a 1-year low of $0.56 and a 1-year high of $2.92. The business’s 50 day simple moving average is $0.68 and its two-hundred day simple moving average is $0.92. The stock has a market cap of $24.54 million, a PE ratio of -0.32 and a beta of -0.63.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. HC Wainwright lifted their price target on shares of Barinthus Biotherapeutics from $3.00 to $4.00 and gave the company a “buy” rating in a research report on Monday, November 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Barinthus Biotherapeutics in a report on Monday, December 22nd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $4.00.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Barinthus Biotherapeutics stock. Renaissance Technologies LLC grew its stake in shares of Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) by 115.8% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 143,100 shares of the company’s stock after buying an additional 76,800 shares during the period. Renaissance Technologies LLC owned approximately 0.35% of Barinthus Biotherapeutics worth $100,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 25.20% of the company’s stock.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.